A hospital for rheumatological diseases in the United Kingdom is participating in an international study that is examining real-world evidence about patient experiences after they switch from reference adalimumab (Humira) to a biosimilar, Imraldi.
A hospital for rheumatological diseases in the United Kingdom is participating in an international study that is examining real-world evidence about patient experiences after they switch from reference adalimumab (Humira) to a biosimilar, Imraldi.
The Pan-EU Real-World Experience with IMRALDI: PROPER Research Study aims to recruit about 1200 to 1400 patients from 60 to 70 treatment centers in the European Union (EU). Patients with rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis are eligible to participate.
The study is taking place at the Royal National Hospital for Rheumatic Diseases (RNHRD) in Bath, part of the Royal United Hospitals Bath NHS Foundation trust, which reported that it just recruited its first patient for the study.
“Randomized controlled trials have demonstrated excellent efficacy for patients to switch from the originator drug to the bio similar,” Raj Sengupta, MD, who is leading the study, said in a statement. “There are, however, very few studies that have looked at real-world evidence—data collected during an observational study—to demonstrate the evidence of the switches. We are very proud to participate in this global study looking at the effectiveness of switching axial spondyloarthritis and psoriatic arthritis patients from Humira, the originator medicine, to Imraldi, the biosimilar in a real-world setting."
In the United Kingdom, which was responsible for the most consumption of brand-name Humira in the European Union as of September 2018, a centralized tender broke the adalimumab market into 11 regions, and awarded shares of the market to multiple bidders. Imraldi took the greatest share, with nearly 45% of the English market.
Imraldi is made by Samsung Bioepis; other biosimilars available in the EU for the treatment of inflammatory diseases are Amgen’s Amgevita, Sandoz’s Hyrimoz, and Mylan’s Hulio.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.